Sylvia serves as Vice President Clinical Operations at Speransa Therapeutics and has been with the company since early 2022. Prior to this, she set up and led the global Clinical Operations department at Affimed, a Heidelberg-headquartered biotech company specialized on the development of therapeutic antibodies in immune-oncology.
Between 2002 and 2017, Sylvia held various leadership positions at Boehringer Ingelheim, Merck KGaA and Topotarget (now Onxeo). During this period, she was mainly responsible for clinical operations of international clinical programs in oncology and inflammatory diseases, where she gained experience with both, new chemical entities (NCEs) as well as biological agents (NBEs and biosimilars).
Before this, as part of her academic career, she was a postdoctoral research fellow at the California Institute of Technology in California for three years. Sylvia obtained her PhD on research in the area of molecular virology/oncology at the Deutsche Krebsforschungszentrum (DKFZ, German Cancer Research Center) in Heidelberg, Germany.